Table 1 Clinicopathologic characteristics of study patients in task 1
Characteristics | Training | P value | Validation | P value | Test | P value | |||
|---|---|---|---|---|---|---|---|---|---|
HER2-negative (n = 283) | HER2-positive (n = 65) | HER2-negative (n = 122) | HER2-positive (n = 27) | HER2-negative (n = 96) | HER2-positive (n = 21) | ||||
Age | Â | Â | 0.99 | Â | Â | 0.62 | Â | Â | 0.40 |
 ≤ 40 | 32(11.31%) | 8(12.31%) |  | 21(17.21%) | 3(11.11%) |  | 13(13.54%) | 5(23.81%) |  |
 >40 | 251(88.69%) | 57(87.69%) |  | 101(82.79%) | 24(88.89%) |  | 83(86.46%) | 16(76.19%) |  |
Menopausal status | Â | Â | 0.11 | Â | Â | 0.64 | Â | Â | 1.00 |
 Premenopausal | 125(44.17%) | 21(32.31%) |  | 54(44.26%) | 10(37.04%) |  | 52(54.17%) | 12(57.14%) |  |
 Postmenopausal | 158(55.83%) | 44(67.69%) |  | 68(55.74%) | 17(62.96%) |  | 44(45.83%) | 9(42.86%) |  |
Ki-67 |  |  | < 0.01 |  |  | < 0.01 |  |  | 0.11 |
 ≤ 20% (low) | 144(50.88%) | 13(20.00%) |  | 78(63.93%) | 6(22.22%) |  | 15(15.62%) | 0(0) |  |
 >20% (high) | 139(49.12%) | 52(80.00%) |  | 44(36.07%) | 21(77.78%) |  | 81(84.38%) | 21(100.00%) |  |
Histomolecular class |  |  | < 0.01 |  |  | < 0.01 |  |  | < 0.01 |
 Luminal | 239(84.45%) | 38(58.46%) |  | 111(90.98%) | 13(48.15%) |  | 84(87.50%) | 11(52.38%) |  |
 HER2-positive | 0(0) | 27(41.54%) |  | 0(0) | 14(51.85%) |  | 0(0) | 10(47.62%) |  |
 Triple negative | 44(15.55%) | 0(0) |  | 11(9.02%) | 0(0) |  | 12(12.50%) | 0(0) |  |
HR status |  |  | < 0.01 |  |  | < 0.01 |  |  | < 0.01 |
 Negative | 45(15.90%) | 27(41.54%) |  | 11(9.02%) | 14(51.85%) |  | 13(13.54%) | 9(42.86%) |  |
 Positive | 238(84.10%) | 38(58.46%) |  | 111(90.98%) | 13(48.15%) |  | 83(86.46%) | 12(57.14%) |  |
LVI | Â | Â | 0.30 | Â | Â | 0.31 | Â | Â | 0.40 |
 Negative | 204(72.08%) | 42(64.62%) |  | 83(68.03%) | 15(55.56%) |  | 71(73.96%) | 13(61.90%) |  |
 Positive | 79(27.92%) | 23(35.38%) |  | 39(31.97%) | 12(44.44%) |  | 25(26.04%) | 8(38.10%) |  |
Clinical T stage | Â | Â | 0.35 | Â | Â | 0.05 | Â | Â | <0.01 |
 T1 | 173(61.13%) | 35(53.85%) |  | 77(63.11%) | 11(40.74%) |  | 49(51.04%) | 2(9.52%) |  |
 T2 or above | 110(38.87%) | 30(46.15%) |  | 45(36.89%) | 16(59.26%) |  | 47(48.96%) | 19(90.48%) |  |
Clinical N stage | Â | Â | 0.89 | Â | Â | 0.16 | Â | Â | 0.76 |
 N0 | 217(76.68) | 51(78.46) |  | 99(81.15%) | 18(66.67%) |  | 70(72.92%) | 14(66.67%) |  |
 N1+ | 66(23.32) | 14(21.54) |  | 23(18.85%) | 9(33.33%) |  | 26(27.08%) | 7(33.33%) |  |
Histology type | Â | Â | 0.03 | Â | Â | 0.20 | Â | Â | 0.58 |
 IBC-NST | 248(87.63%) | 63(96.92%) |  | 105(86.07%) | 26(96.30%) |  | 91(94.79%) | 21(100.00%) |  |
 ILC or others | 35(12.37%) | 2(3.08%) |  | 17(13.93%) | 1(3.70%) |  | 5(5.21%) | 0(0) |  |
Grade | Â | Â | 0.14 | Â | Â | 0.04 | Â | Â | 0.04 |
 I or II | 187(66.08%) | 36(55.38%) |  | 94(77.05%) | 15(55.56%) |  | 54(56.25%) | 6(28.57%) |  |
 III | 96(33.92%) | 29(44.62%) |  | 28(22.95%) | 12(44.44%) |  | 42(43.75%) | 15(71.43%) |  |